Egypt has the highest prevalence of chronic hepatitis C virus (HCV) infection worldwide with the development of cirrhosis and hepatocellular carcinoma (HCC). The hepatocyte growth factor (HGF)-cMET axis promotes cell survival, proliferation, migration, and invasion. This study aimed to evaluate the role of serum HGF as a noninvasive biomarker in the diagnosis of liver cirrhosis and HCC.
Introduction
Liver cirrhosis represents the fi nal stage of several chronic hepatic diseases [1] . It is a diff use process of architectural disorganization characterized by fi brosis and the formation of structurally abnormal parenchymal nodules [2] . Th is results in portal hypertension, portosystemic shunting, and a decrease in the eff ective parenchymal mass [3] . Cirrhosis is a dynamic condition, where two extreme processes occur: fi brogenesis and fi brolysis [4] . Progressive accumulation of collagen as well as other proteins in the extracellular matrix eventually results in disrupted liver morphology, parenchymal function impairment, and ultimately portal hypertension and its related sequels [5] .
Hepatocellular carcinoma (HCC) ranks as the fi fth most common cancer worldwide and the third most frequent cause of cancer-related death [6] . It is one of the fastest tumors resulting from chronic infection by hepatitis B and C viruses [7] . It represents the most common primary malignant tumor of the liver and is one of the major causes of death among patients with cirrhosis [6, 8] .
Signifi cance of hepatocyte growth factor concentrations in serum of patients with liver cirrhosis and patients with hepatocellular carcinoma
In 2001, HCC in Egypt was reported to account for about 4.7% of chronic liver disease patients. In another study, in 2005, a marked increase from 4 to 7.2% was reported over a decade. Patients with advanced liver disease, particularly cirrhosis, are those at risk for HCC and should be screened every 6 months for its development [9] .
HCC generally develops following an orderly progression from cirrhosis to dysplastic nodules to early cancer development, which can be cured reliably if discovered before the development of vascular invasion [10] .
Among patients with chronic hepatitis C, serum α-fetoprotein (AFP) values are frequently elevated, even in the absence of HCC. Factors associated with elevated AFP include severity of liver disease, female sex, and Black race [11] .
Hepatocyte growth factor (HGF) is a multifunctional factor that is produced in various body organs and can aff ect mitogenesis, cell motility, matrix invasion, and epithelial carcinogenesis [12] .
HGF exerts its actions through tyrosine phosphorylation of its receptor, cMET, which is a proto-oncogene product. HGF exerts protective eff ects on epithelial and nonepithelial organs (including the heart and brain) through antiapoptotic and anti-infl ammatory signals. During organ diseases, plasma HGF levels increase signifi cantly. Th us, endogenous HGF is required for minimization of diseases, whereas insuffi cient production of HGF leads to organ failure. Moreover, emerging studies have delineated key roles of HGF during tumor metastasis, whereas HGF antagonism leads to antitumor outcomes [13] .
Under normal physiological conditions, the HGF and its receptor, the MET transmembrane tyrosine kinase (cMET), are involved in embryogenesis, morphogenesis, and wound healing. Th e HGF-cMET axis promotes cell survival, proliferation, migration, and invasion through modulation of epithelial-mesenchymal interactions. HGF transcription is upregulated by infl ammatory modulators such as tumor necrosis factor α, IL-1, IL-6, transforming growth factor-β, and vascular endothelial growth factor (VEGF) [14] .
HGF suppresses the increase in transforming growth factor-β1, which plays an essential role in the progression of liver cirrhosis with a decrease in profi brogenic markers such as collagen expression and a-smooth muscle actin and inhibition of fi brogenesis. HGF has also been shown to prevent tissue fi brosis in the kidneys by increasing MMP-9 and suppressing expression of TIMP-1. It also upregulates the antiapoptotic protein Bcl-xL. It has been shown previously that the intrahepatic expression of HGF-specifi c receptor cMET decreases at an early stage of cirrhosis development and signifi cantly decreases at the time of cirrhosis manifestation, leading to decreased antifi brotic eff ects despite elevated levels of HGF [15] .
HGF (also known as the scattering factor) activates the MET signaling pathway, thereby increasing the invasive and metastatic potential of the cells and allowing the survival of cancer cells in the blood stream and facilitating cancer progression [16] . Dysregulated cMET signaling upregulates protease production (plasminogen dependent and independent) and increased cell dissociation through extracellular matrix degradation, facilitating tumor invasiveness and metastasis. Cross-talk between cMET and epidermal growth factor receptor and cMET and VEGF signaling pathways is also implicated in promoting tumor survival. HGF-cMET signaling induces upregulation of VEGF expression and endothelial VEGFR2 expression and downregulation of endogenous inhibitors of angiogenesis [14] . In HCC, the mRNA levels of HGF and the MET receptor are markedly increased compared with those in normal liver. A high serum HGF concentration is associated with a poor prognosis for overall survival after hepatic resection, and the serum level of HGF represents the degree of the carcinogenic state in the livers of patients with C-viral chronic hepatitis and cirrhosis [16] .
Patients and methods
Th is is a cross-sectional observational comparative study that was carried out in Kasr Al Ainy Internal Medicine Clinic on 80 individuals. All patients were informed about their inclusion in the study. Th e study was approved by the ethical committee of chemical pathology department. Th e participants were divided into three groups: group 1 included 20 healthy volunteers as a control group, group 2 included 30 patients with liver cirrhosis, and group 3 included 30 patients with HCC. All patients were diagnosed by clinical examination, biochemical investigations, abdominal ultrasonography, and abdominal triphasic computed tomography.
All patients were positive for hepatitis C virus (HCV) as evidenced by positive HCV IgG antibody detected by the ELISA technique. Written informed consents were obtained from all participants.
Exclusion criteria were as follows: spontaneous bacterial peritonitis, infl ammatory bowel disease, systemic sepsis, other types of malignancy, diabetes mellitus, chronic renal failure, lung diseases, and vascular or cardiac disorders.
Methods

Blood sample
Ten milliliters of venous blood was withdrawn from each participant. Th e samples were divided as follows:
(1) Two milliliters collected in an EDTA tube for complete blood count. (3) Th e rest of the sample was collected in a plain tube, left to clot, and then serum was separated and divided into three aliquots: one for blood chemistry, which was assayed on the same day as sample collection, and the second and the third for AFP and HGF, which were stored at -20°C until the time of assay.
All patients and controls in this study were subjected to the following:
Liver function tests including serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), serum alkaline phosphatase (ALP), serum γ-glutamyl transferase (GGT), and serum total bilirubin, serum albumin, and serum total protein. Th e liver functions were assayed using the chemistry autoanalyzer (Dimension from Dade Behring RXL, version 5.2; Siemens Healthcare Diagnostic Inc., Newark, Delaware, USA).
Red blood cells, white blood cells, and platelet counts, hemoglobin concentration, PT, PC, and INR were also determined.
To determine the stage of hepatic fi brosis in our cases, the following equations were used: APRI: AST level (in IU/l, divided by the upper limit of normal) and platelet count (in 10 9 cells/l) were measured, respectively [17] .
Fibroindex: this was measured using the following equation [18] :
Model 3: this index may be derived from the following regression formula [19] :
Log odds = −5.56 −0.0089 ×platelet (×10 9 /1) +1.26 ×AST/ALT ratio +5.27 ×INR.
Serum AFP was assayed using the electrochemiluminescence technique (Bayer Healthcare LLC, Tarry Town, New York, USA) [20] .
Serum HGF was assayed by the quantitative sandwich ELISA technique using HGF ELISA kit (catalog no. DHG00; R&D Systems Inc., Minneapolis, Minnesota, USA) [21] .
Statistical analysis
Th e results were analyzed using the SPSS computer software package (version 13; SPSS Inc., Chicago, Illinois, USA). Quantitative data were presented as mean ± SD for normally distributed data and as medians and percentiles for skewed data. Qualitative data were presented in the form of frequencies and percentiles. Diff erences among groups were determined using one-way analysis of variance with post-hoc test and Kruskal-Wallis analysis of variance, and/or the Mann-Whitney test for normally distributed and skewed data, respectively. Th e Pearson χ 2 -test and/or Fisher's exact test were used to detect associations between two variables. For correlations between variables, Pearson's and/or Spearman's correlation coeffi cients were calculated. All tests were two tailed and considered statistically signifi cant at P value less than 0.05. Multiple receiver operating characteristic curves were constructed by calculating sensitivities and specifi cities of the studied analytes at diff erent cut-off points.
Results
Comparison between the three groups, normal control participants, patients with liver cirrhosis, and patients with HCC, showed no signifi cant diff erence in terms of age and sex, but the hematological data were signifi cantly diff erent. Th e indices of fi brosis, AFP, and HGF were signifi cantly higher in the HCC group compared with the other two groups ( Table 1) .
Th e radiological data of the cirrhosis group and the HCC group for detection of cirrhosis, splenomegaly, ascites, and portal hypertension were not signifi cant. Th e number of masses in the HCC group showed one mass in 22 patients, two masses in fi ve patients, and three masses in three patients ( Table 2) .
HGF is signifi cantly correlated with all parameters, except AST/ALT, number of masses, mss size, and total proteins. Upon correlation of HGF with the number of masses in the HCC group, we found that the value of HGF tended to be higher with the number of masses, but this was not statistically signifi cant because of the small number of patients (Tables 3 and 4 
and Figs 1-21).
Th e area under the receiver operating characteristics curve of HGF and AFP for the HCC group versus both the cirrhotic and the control groups were 0.787 and 0.999, respectively.
Th e odds ratio and 95% confi dence interval for HGF were 11.926 and 2.56-55.55, respectively. 
Discussion
HCC represents the fi fth most common cancer in the world and the third most frequent cause of mortality among oncological patients [10] . Egypt has the highest prevalence of chronic HCV infection worldwide, ranging from 6% to more than 40% among regions and demographic groups, leading to increasing rates of HCC [22] .
HCV is a major cause of liver disease and it is considered the most common cause of chronic liver disease in Egypt. Although HCV infection is often asymptomatic, it is likely to progress to cirrhosis and HCC; 20% of chronic hepatitis C patients develop cirrhosis after 10-20 years [23] . Early detection of patients with HCC is useful because it yields a better prognosis as HCC tends to grow slowly and remains confi ned to the liver. Early detection is possible with ultrasound scanning and AFP monitoring, although the use of AFP as a screening test is complicated by frequent false-positive and false-negative results [24] . HGF, or scatter factor, was fi rst identifi ed as a factor Correlations between hepatocyte growth factor (HGF) and α-fetoprotein (AFP) for all the participants studied. There is a positive correlation between HGF and AFP for all patients (groups 2 and 3) (P = 0.000 and r = 0.561 ).
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Figure 2
Correlation between hepatocyte growth factor (HGF) and aspartate aminotransferase (AST ).
Correlation between hepatocyte growth factor (HGF) and alanine aminotransferase (ALT ).
Figure 3
Correlation between aspartate aminotransferase (AST)/alanine aminotransferase (ALT ).
Figure 4
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Correlation between hepatocyte growth factor (HGF) and alkaline phosphatase (ALP ).
Figure 5
Correlation between hepatocyte growth factor (HGF) and γ-glutamyl transferase (GGT ).
Figure 6
Correlation between hepatocyte growth factor (HGF) and total bilirubi n.
Figure 7
Correlation between hepatocyte growth factor (HGF) and model 3.
Figure 8
Correlation between hepatocyte growth factor (HGF) and fi broinde x.
Figure 9
Correlation between hepatocyte growth factor (HGF) and α-fetoprotein (AFP ).
Figure 10
from plasma from humans and rabbits, and also rat platelets that could induce the proliferation of hepatocytes in culture. Following its initial discovery, HGF was shown to be produced primarily by mesenchymal cell types, especially fi broblasts, in a variety of tissues including the lung, heart, kidney, liver, skin, and brain [25] .
The aim of this study was to assess the serum level of HGF and AFP in patients with liver cirrhosis Correlation between hepatocyte growth factor (HGF) and number of masse s.
Figure 11
Correlation between hepatocyte growth factor (HGF) and prothrombin time (PT ).
Figure 13
Correlation between hepatocyte growth factor (HGF) and prothrombin concentration (PC% ).
Figure 14
Correlation between hepatocyte growth factor (HGF) and size of masse s.
Figure 12
Correlation between hepatocyte growth factor (HGF) and white blood cells (WBCs ).
Figure 16
Correlation between hepatocyte growth factor (HGF) and international normalized ratio (INR ).
Figure 15
with HCV infection and those of HCC, in addition to HCV, and to compare them with normal individuals to evaluate the role of serum HGF as a noninvasive biomarker in the diagnosis of liver cirrhosis and HCC. This study was carried out on 80 individuals divided into three groups: group 1 included 20 healthy control participants, group 2 included 30 patients with HCV infection and liver cirrhosis, and finally, group 3 included 30 patients with HCC, in addition to HCV infection and liver cirrhosis.
In our study, the serum HGF levels were 535-1529, 925-7481, and 1369-8717 pg/ml in the control, cirrhotic, and HCC groups, respectively. HGF was highly signifi cantly elevated in the HCC group [median 3709 (2574.5-5128.75) pg/ml] and the cirrhotic group [median 2843.5 (2119-3721) pg/ml] compared with that of the control group [median 913 (770.7-1166.5) pg/ml] (P = 0.000).
Several researchers have confi rmed similar results of increased HGF levels in patients with liver cirrhosis and HCC compared with normal control participants such as the studies of Shiota et al. [26] and Vejchapipat et al. [27] . In our study, the level of HGF was higher in the HCC group than that in the cirrhotic group, but this diff erence was not statistically signifi cant.
However, Yamagamim et al. [28] , found that the mean serum HGF concentration was signifi cantly higher in patients with HCC than in patients with chronic hepatitis or cirrhosis.
Karabulut et al. [29] found that the baseline serum HGF levels were signifi cantly higher in patients with HCC than in the control group (P < 0.001).
Th e serum AFP levels in our study were 1.2-8.4, 2.6-30, and 25.9-745 ng/ml in the control, the cirrhotic, and the HCC group, respectively.
Correlation between hepatocyte growth factor (HGF) and albumi n.
Figure 20
Correlation between hepatocyte growth factor (HGF) and red blood cells (RBCs ).
Figure 17
Correlation between hepatocyte growth factor (HGF) and hemoglobin (Hb ).
Figure 18
Correlation between hepatocyte growth factor (HGF) and platelet s.
Figure 19
Th e AFP level was highly signifi cantly increased in the HCC group [median 128.5 (81.75-239.5) ng/ml] than both the cirrhotic group [median 4.9 (3.65-8.55) ng/ml] and the control group [median 3.15 (1.97-4.55) ng/ml] (P = 0.000). Th e AFP level of the cirrhotic group was still higher than that of the control group, but this diff erence was not statistically signifi cant. Similar to our results, Jia et al. [30] found that serum AFP level was signifi cantly higher in HCC patients than in liver cirrhosis patients and healthy individuals. Th e results from the studies of Hussein et al. [9] and Cheng et al. [31] yielded the same results. Gadelhak et al. [32] found a signifi cantly elevated AFP level in the HCC group than that in the healthy group.
El Badrawy et al. [33] , in their study in 2013, reported that tissue expression of AFP showed positivity in cirrhosis and high expression in HCC and that of HGF was higher in the liver cirrhosis and HCC groups compared with the control group.
Our study showed that the fi brotic indices AST/ALT, APRI, fi broindex, and model 3 were signifi cantly higher in the cirrhotic group compared with the control group (P = 0.006 for all), confi rming their role as noninvasive markers for liver fi brosis. Th ese results were in agreement with those of Lackner et al. [34] as these fi brotic indices can enable the diagnosis of liver cirrhosis.
In our study, we found a positive signifi cant correlation between HGF and AFP for all the participants studied (r = 0.561, P = 0.000); however, we did not fi nd this correlation in each group separately. Th e same results were reported by Yamagamim et al. [28] .
In our study, there were direct correlations between HGF and APRI, fi broindex, and model 3 ( Table 3) .
Our study showed direct signifi cant correlations between HGF and each of AST, ALT, ALP, GGT, and total bilirubin in all the participants studied (r = 0.653, P = 0.000; r = 0.458, P = 0.000; r = 0.501, P = 0.000; r = 0.289, P = 0.009; and r = 0.487, P = 0.000; respectively). Th e same positive correlations were reported in the study by Shiota et al. [26] , but Yamagamim et al. [28] showed that serum HGF level was not signifi cantly correlated with other indicators of liver functions, such as the AST level, the ALP level, and the GGT level.
Karabulut et al. [29] found that male patients had higher serum HGF levels compared with female patients (P = 0.01). Serum HGF levels were signifi cantly higher in the patients with elevated serum ALT levels than others with normal serum ALT levels (P = 0.05) [29] .
Our study also showed indirect signifi cant correlations between HGF and albumin in all the participants studied (r = −0.508, P = 0.000) as shown in Table 3 and direct signifi cant correlations between HGF and each of PT and INR in all the participants studied (r = 0.571, P = 0.000 and r = 0.611, P = 0.000, respectively) as shown in Table 5 . Shiota et al. [26] , found the same correlation with albumin, but in their study, serum HGF levels showed a negative correlation with PT.
Upon correlation of HGF with the number of masses in the HCC group, we found that the value of HGF tends to be higher with the number of masses, but this was not statistically signifi cant because of the small number of patients.
Th e sensitivity and specifi city of HGF have been shown to vary with the diff erent cut-off values used. According to our results, at a cut-off 1451 pg/ml (1.451 ng/ml), the sensitivity was 93.3%, the specifi city was 46%, and area under the curve (AUC) was 0.787.
Th e concentration of HGF (mean 3.69 vs. 5.58 ng/ml, AUC 0.71) was found in the study of Andersen et al. [35] , and it was signifi cantly higher (among other studied parameters) in patients with cirrhosis.
Yamagamim et al. [28] found in their study that the cut-off value of HGF for suspecting HCC in their cirrhotic patients was above 0.6 ng/ml and they concluded from their study that HGF may be a critical marker for emergence of HCC in their patients. Of course, they detected the HGF after only two days of storage of their samples, which is why their values were low and more specifi c [28] . In our study, our samples were stored till the end of collection; this explains the higher cut-off value and the decreased specifi city.
Correlation between hepatocyte growth factor (HGF) and protein s.
Figure 21
Th e sensitivity and specifi city of AFP have been shown to vary with the diff erent cut-off values used. In our study, at a cut-off of 10 ng/ml, the sensitivity was 100%, the specifi city was 92%, and AUC was 0.999.
Taketa et al. [36] reported a sensitivity of 95% and a specifi city of 66% for AFP when the cut-off value was 10 ng/ml. Gad et al. [37] detected 99% sensitivity and 75% specifi city for AFP for the diagnosis of HCC in Egyptian patients at a cut-off value of 10 ng/ml. Hussein et al. [9] found that the sensitivity and specifi city of AFP at a cut-off value of 7.7 ng/ ml were 89.8 and 93.3%, respectively, Stefaniuk et al. [38] reported that the sensitivity and specifi city of AFP at a cut-off value of 20 ng/ml were 60 and 90%, respectively, Chen et al. [39] reported that the sensitivity and specifi city of AFP were 72 and 78% when the cut-off value was 20 ng/ml, and Lok et al. [40] reported that the sensitivity and specifi city of AFP were 61 and 81% at a cut-off value of 20 ng/ml. Sheng et al. [41] found that AUC for AFP was 0.771, Marrero et al. [42] found that AUC for AFP was 0.8, and Yamamoto et al. [43] found that AUC was 0.79 for AFP.
Zhou et al. [44] found that the serum AFP level is associated with more clinicopathological variables of HCC at a cut-off value of 400 ng/ml than 20 ng/ml. However, serum AFP level at a cut-off value of 20 ng/ml is of signifi cant prognostic impact for both overall and tumor-free survival, whereas that under 400 ng/ml is not.
We conclude from this study that both HGF and AFP can be additional useful factors as noninvasive biomarkers for the early detection of HCC in HCV cirrhotic patients cause that the specifi city of HGF is only 46% yet the specifi city of AFP is 92%. Of course, this is highly premature to establish as a wellestablished fact because to confi rm our fi ndings, we need a large-scale study of Egyptian patients using the same parameters as well as the noninvasive markers for liver fi brosis instead of the invasive liver biopsy, especially as those markers were positively correlated with both HGF and AFP and delineated in a great way the liver pathological status of the patients in our study. We also need to evaluate the HGF in our samples within 48 h of the extraction of blood to avoid the spurious increase in HGF in stored samples, which may have altered the specifi city and the cutoff value in our study. We also need to extend our research to include a large number of HCC patients with diff erent numbers of masses and to correlate the number of these masses with the value of HGF. For the future, we must carry out genetic polymorphism studies of HGF.
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